0001477932-22-002952.txt : 20220504 0001477932-22-002952.hdr.sgml : 20220504 20220504161658 ACCESSION NUMBER: 0001477932-22-002952 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001187953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870622284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-264455 FILM NUMBER: 22891722 BUSINESS ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 BUSINESS PHONE: 480-399-2822 MAIL ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 FORMER COMPANY: FORMER CONFORMED NAME: JOLLEY MARKETING INC DATE OF NAME CHANGE: 20020910 RW 1 celz_rw.htm RW celz_rw.htm

Creative Medical Technology Holdings, Inc.

211 E. Osborn Road

Phoenix, Arizona 85012

 

May 4, 2022

Via Edgar

 

Mr. Daniel Crawford

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

 

 

Re:

Creative Medical Technology Holdings, Inc.

Request for Withdrawal of Registration Statement on Form S-1

Filed April 22, 2022

File No. 333-264455

 

Dear Ms. Crawford:

 

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Creative Medical Technology Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement be withdrawn, effective as of the date hereof. The Company is withdrawing the Registration Statement because it no longer plans to consummate the offering of its securities described in the Registration Statement. The Registration Statement has not been declared effective by the Securities and Exchange Commission (the “SEC”), and no securities have been issued or sold thereunder. Accordingly, the Company believes that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors.

 

The Company requests that, in accordance with Rule 457(p) of the Securities Act and subject to compliance with the requirements thereof, all fees paid to the SEC in connection with the filing of the Registration Statement be credited for future use.

 

Please contact Zev M. Bomrind of Fox Rothschild LLP, counsel to the Company, at (212) 878-7951, if you have any questions or concerns regarding this matter.

 

 

Sincerely,
   
/s/ Timothy Warbington                    

 

 Timothy Warbington  
 

Chief Executive Officer